Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?

Circulation

Volumn 110, Issue 17, 2004, Pages 2552-2558

  Shoenfeld, Yehuda ^a,b   Wu, Ruihua ^c   Dearing, Linda D ^d   Matsuura, Eiji ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RDL Reference Laboratory   (United States)

^d Specialty Laboratories   (United States)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antibodies; Atherosclerosis; Cardiovascular diseases; Editorials; Lipoproteins

Indexed keywords

AUTOANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; EDITORIAL; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; AUTOANTIBODIES; AUTOANTIGENS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL;

EID: 7544229779     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143225.07377.EA     Document Type: Editorial

References (105)

1. Shoenfeld Y, Harats D, Wick G, eds. Atherosclerosis and Autoimmunity. Amsterdam: Elsevier; 2001:1-370.
2. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond). 1993a;362:801-809.
4. Ross R. Mechanisms of disease: atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
5. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332-1339.
6. Nakashima Y, Raines EW, Plump AS, et al. Up-regulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-851.
7. Sakai A, Kume N, Nishi E, et al. P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol. 1997;17:310-316.
8. Ross R. Rous-Whipple Award Lecture: Atherosclerosis: a defense mechanism gone awry. Am J Pathol. 1993b;143:987-1002.
9. von der Thusen JH, Kuiper J, van Berkel TJC, et al. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003;55:133-166.
10. Georges JL, Rupprecht HJ, Blankenberg S, et al., for the AtheroGene Group. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol. 2003;92:515-521.
11. George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis. 1998;138:147-152.
12. George J, Shoenfeld Y, Afek A, et al. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler Thromb Vasc Biol. 1999;19:505-510.
13. 2-glycoprotein 1 (apolipoprotein H) to human atherosclerosis plaques: potential implications for lesion progression. Circulation. 1999;99:2227-2230.
14. 2-glycoprotein I: reactive lymphocytes enhance early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000;102:1822-1827.
15. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2243-2247.
16. Zhao D, Ogawa H, Wang X, et al. Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. Am J Clin Pathol. 2001;116:760-767.
17. Frostegard J, Wu R, Lemne C, et al. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci. 2003;105:615-620.
18. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487-1494.
19. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002;22:1162-1167.
20. Boyd HC, Gown AM, Wolfbauer G, et al. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol. 1989;135:815-825.
21. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
22. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
23. Holvoet P, Srtassen JM, Van Cleemput J, et al. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:100-107.
24. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
25. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
26. Cvetkovic JT, Wallberg-Jonsson S, Ahmed E, et al. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41:988-995.
27. Virella G, Virella I, Leman RB, et al. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993;23:95-101.
28. Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17:3159-3163.
29. Puurunen M, Mänttäri M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
30. Wu R, Svenungsson E, Gunnarsson I, et al. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus. 1999;8:142-150.
31. Nagahama M, Nomura S, Kanazawa S, et al. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in antiphospholipid antibody syndrome. Autoimmunity. 2003;36:125-131.
32. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
33. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;11:1218-1226.
34. George J, Blank M, Hojnik M, et al. Oxidized low-density lipoprotein (Ox LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS). Clin Exp Immunol. 1997;108:227-233.
35. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidized low density lipoprotein forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res. 2003;44:716-726.
36. Matsuura E, Kobayashi K, Koike T, et al. Atherogenic autoantigen: oxidized LDL complexes with β2-glycoprotein I. Immunobiology. 2003;207:17-22.
37. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb. 1992;12:206-211.
38. Stemme S, Faber B, Holm J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-3897.
39. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
40. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
41. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotope, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol. 1995;102:174-180.
42. Zhou X, Caligiuri G, Hamsten A, et al. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arteriosder Thromb Vasc Biol. 2001;21:108-114.
43. Dimayuga P, Cercek B, Oguchi S, et al. Inhibitory effect on arterial injury-induced neointimal formation by adoptive B-cell transfer in Rag-1 knockout mice. Arteriosder Thromb Vasc Biol. 2002;22:644-649.
44. Caligiuri G, Nicoletti A, Poirier B, et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest. 2002;109:745-753.
45. Shoenfeld Y, Haratz D, George J. Heat shock protein 60/50, beta2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. J Autoimmunity. 2000;15:199-202.
46. Caligiuri G, Rudling M, Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003;9:10-17.
47. Keren G, Keren P, Barshack I, et al. The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury. Atherosclerosis. 2001;159:77-83.
48. Iughetti L, Volta C, Maggi E, et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr Res. 1999;45:94-99.
49. Wu R, de Faire U, Lemne C, et al. Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension. 1999;33:53-59.
50. Lopes-Virella MF, Virella G, Orchard TJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol. 1999;90:165-172.
51. Shoji T, Nishizawa Y, Fukumoto M, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 2000;148:171-177.
52. Fukumoto M, Shoji T, Emoto M, et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol. 2000;20:703-707.
53. Ylä-Herttuala S, Palinski W, Butler SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
54. George J, Ahmed A, Patnaik M, et al. The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol. 2000;23:453-456.
55. George J, Harats D, Bakshi E, et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett. 1999;68:263-266.
56. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arteriosder Thromb Vasc Biol. 1995;15:441-445.
57. Ben-Yehuda O, Witztum JL, Keaney JF, et al. Autoantibody titer to malondialdehyde modified low density lipoprotein correlates with extent of coronary artery disease. Circulation. 94(suppl 1):1-638, 1996.
58. Maggi E, Finardi G, Poli M, et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis. 1993;4:1119-1122.
59. Fang JC, Kinlay S, Behrendt D, et al. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arteriosder Thromb Vasc Biol. 2002;22:2044-2048.
60. Maggi G, Chiesa R, Melissano G, et al. LDL oxidation in patients with severe carotid atherosclerosis. Arterioscler Thromb. 1994;14:1892-1899.
61. Monaco C, Crea F, Niccoli G, et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: pathophysiological implications. Eur Heart J. 2001;22:1572-1577.
62. Swets BP, Brouwer DA, Tervaert JW. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol. 2001;124:163-167.
63. Dotevall A, Hulthe J, Rosengren A. et al. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women. Clin Sci (Lond). 2001;101:523-531.
64. Sherer Y, Tenenbaum A, Praprotnik S, et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology. 2001;95:20-24.
65. Raitakari OT, Pitkanen OP, Lehtimaki T, et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol. 1997;30:97-102.
66. Maggi E, Marchesi E, Ravetta V, et al. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens. 1995;13:129-138.
67. Virella G, Atchley D, Koskinen S, et al. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol. 2002;105:81-92.
68. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol. 1996;16:222-229.
69. Wu R, Shoenfeld Y, Sherer Y, et al. Anti-idiotypes oxidized LDL antibodies in intravenous immunoglobulin preparations: possible immunomodulation of atherosclerosis. Autoimmunity. 2003;36:91-97.
70. Devey ME, Voak D. A critical study of the IgG subclasses of Rh anti-D antibodies formed in pregnancy and in immunized volunteers. Immunology. 1974;27:1073-1079.
71. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A. 1981;78:6499-6503.
72. Wu R, Svenungsson E, Gunnarsson I, et al. Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus. Clin Exp Immunol. 1999;115:561-566.
73. Hayem G, Nicaise-Roland P, Palazzo E, et al. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus. 2001;10:346-351.
74. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-1893.
75. Orchard TJ, Virella G, Forrest KY, et al. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes. Diabetes. 1999;48:1454-1458.
76. Bellomo G, Maggi E, Poli M, et al. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 1995;44:60-66.
77. Maggi E, Bellazzi R, Gazo A, et al. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney Int. 1994;46:869-876.
78. Heitzer T, Yla-Herttuala S, Luoma J, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation. 1996;93:1346-1353.
79. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990;114:383-387.
80. Branch DW, Mitchell MD, Miller E, et al. Pre-eclampsia and serum antibodies to oxidized low-density lipoprotein. Lancet. 1994;343:645-646.
81. Motta M, Pistone G, Franzone AM, et al. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma. Panminerva Med. 2003;45:69-73.
82. Brizzi P, Isaja T, D'Agata A, et al. Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J Atheroscler Thromb. 2002;9:139-144.
83. Orem A, Cimsit G, Deger O, et al. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Clin Chim Acta. 1999;284:81-88.
84. Uotila J, Solakivi T, Jaakkola O, et al. Antibodies against copper-oxidised and malondialdehyde-modified low density lipoproteins in pre-eclampsia pregnancies. Br J Obstet Gynaecol. 1998;105:1113-1117.
85. 2. Arterioscler Thromb Vasc Biol. 2001;21:269-274.
86. Uusitupa M, Niskanen L, Luoma J, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:1236-1242.
87. Mironova MA, Klein RL, Virella GT, et al. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes. 2000;49:1033-1041.
88. Eber B, Schumacher M, Tatzber F, et al. Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. Cardiology. 1994;84:310-315.
89. Ahmed E, Trifunovic J, Stegmayr B, et al. Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke. 1999;30:2541-2546.
90. Iribarren C, Folsom AR, Jacobs DR Jr, et al. Association of serum vitamin levels, LDL, susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1171-1177.
91. Paiker JE, Raal FJ, von Arb M. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem. 2000;37:174-178.
92. Van de Vijver LPL, Steyger R, von Poppel G, et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis. 1996;122:245-253.
93. Heikkinen A-M, Niskanen L, Yla-Herttuala S, et al. Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas. 1998;29:155-161.
94. Zezina L, Dimeny E, Vessby B, et al. Serum levels of antibodies against oxidized LDL in kidney graft recipients. Am J Nephrol. 2002;22:539-547.
95. Nicoletti A, Kaveri S, Caligiuri G, et al. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest. 1998;102:910-918.
96. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol. 2002;14:1303-1311.
97. Krause I, Blank M, Sherer Y, et al. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol. 2002;32:3414-3424.
98. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003;9:736-743.
99. Mathews JD, Whittingham S, Mackay IR. Autoimmune mechanisms in human vascular disease. Lancet. 1974:1423-1427.
100. Steinberg D, Witztum JL. Lipoproteins and atherosclerosis: current concepts. JAMA. 1990;264:3047-3052.
101. Karvonen J, Paivansalo M, Kesaniemi YA, et al. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation. 2003;108:2107-2112.
102. Show PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act on atherosclerosis, apoptotic clearance and protective immunity. J Clin Invest. 2000;105:1731-1740.
103. Hansson GK. Vaccination against atherosclerosis. Circulation. 2002;106:1599-1601.
104. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071-1077.
105. Shoenfeld Y, Sherer Y, Haratz D. Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001;22:293-295.